Abstract
Background: Type 2 diabetes may be a more heterogeneous disease than previously thought. Better understanding of pathophysiological subphenotypes could lead to more individualized diabetes treatment. We examined the characteristics of different phenotypes among 5813 Danish patients with new clinically diagnosed type 2 diabetes. Methods: We first identified all patients with rare subtypes of diabetes, latent autoimmune diabetes of adults (LADA), secondary diabetes, or glucocorticoid-associated diabetes. We then used the homeostatic assessment model to subphenotype all remaining patients into insulinopenic (high insulin sensitivity and low beta cell function), classical (low insulin sensitivity and low beta cell function), or hyperinsulinemic (low insulin sensitivity and high beta cell function) type 2 diabetes. Results: Among 5813 patients diagnosed with incident type 2 diabetes in the community clinical setting, 0.4% had rare subtypes of diabetes, 2.8% had LADA, 0.7% had secondary diabetes, 2.4% had glucocorticoid-associated diabetes, and 93.7% had WHO-defined type 2 diabetes. In the latter group, 9.7% had insulinopenic, 63.1% had classical, and 27.2% had hyperinsulinemic type 2 diabetes. Classical patients were obese (median waist 105 cm), and 20.5% had cardiovascular disease (CVD) at diagnosis, while insulinopenic patients were fairly lean (waist 92 cm) and 17.5% had CVD (P = 0.14 vs classical diabetes). Hyperinsulinemic patients were severely obese (waist 112 cm), and 25.5% had CVD (P < 0.0001 vs classical diabetes). Conclusions: Patients clinically diagnosed with type 2 diabetes are a heterogeneous group. In the future, targeted treatment based on pathophysiological characteristics rather than the current “one size fits all” approach may improve patient prognosis.
| Original language | English |
|---|---|
| Article number | e3005 |
| Journal | Diabetes/Metabolism Research and Reviews |
| Volume | 34 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Jul 2018 |
Funding
This study was supported by the Danish Agency for Science (grant nos. 09‐067009 and 09‐075724), the Danish Health and Medicines Authority, the Danish Diabetes Association, and the Region of Southern Denmark. The DD2 biobank was supported by an unrestricted donation from Novo Nordisk A/S. The partners of the DD2 project are listed on the website, https://dd2.nu. The sponsors of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. Dr Olsen reports partial funding by a clinical research grant from the Novo Nordisk Foundation. Dr Henriksen reports grants from the Danish Agency for Science (grant nos. 09‐067009 and 09‐075724) for the conduct of the study. He is also a member of the MSD National Advisory Board. Dr Rungby reports personal fees from Novo Nordisk, Eli Lilly, Astra Zeneca, and Takeda outside the submitted work. Dr Toft Sorensen reports that the Department of Clinical Epidemiology, Aarhus University Hospital, receives funding for other studies from companies in the form of research grants to (and administered by) Aarhus University. None of those studies have any relation to the present study. Dr Beck‐Nielsen reports grants from the Danish Agency for Science (grant nos. 09‐067009 and 09‐075724) and an unrestricted grant from Novo Nordisk for the conduct of this study, and personal lecture fees from Novo Nordisk, outside the submitted work. All other authors declare no competing interests.
Keywords
- clinical diabetes
- individualized treatment
- insulin secretion
- insulin sensitivity and resistance
- pathophysiology
- treatment guidelines
Fingerprint
Explore the research areas of 'Pathophysiology-based phenotyping in type 2 diabetes: A clinical classification tool'.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver